HBV
MCID: HPT016
MIFTS: 70

Hepatitis B (HBV)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis B

MalaCards integrated aliases for Hepatitis B:

Name: Hepatitis B 38 12 76 55 43 44 15 73
Hepatitis B Infection 12 15
Hepatitis B, Chronic 73
Chronic Hepatitis B 12
Hepatitis B Chronic 55
Serum Hepatitis 12
Hbv 48

Classifications:



External Ids:

Disease Ontology 12 DOID:2043
MeSH 44 D006509
NCIt 50 C3097
SNOMED-CT 68 66071002

Summaries for Hepatitis B

MedlinePlus : 43 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. One type, hepatitis B, is caused by the hepatitis B virus (HBV). Hepatitis B spreads by contact with an infected person's blood, semen, or other body fluid. An infected woman can give hepatitis B to her baby at birth. If you get HBV, you may feel as if you have the flu. You may also have jaundice, a yellowing of skin and eyes, dark-colored urine, and pale bowel movements. Some people have no symptoms at all. A blood test can tell if you have it. HBV usually gets better on its own after a few months. If it does not get better, it is called chronic HBV, which lasts a lifetime. Chronic HBV can lead to cirrhosis (scarring of the liver), liver failure, or liver cancer. There is a vaccine for HBV. It requires three shots. All babies should get the vaccine, but older children and adults can get it too. If you travel to countries where Hepatitis B is common, you should get the vaccine. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis B, also known as hepatitis b infection, is related to hepatitis d and hepatitis, and has symptoms including fever, vomiting and fatigue. An important gene associated with Hepatitis B is LAMTOR5 (Late Endosomal/Lysosomal Adaptor, MAPK And MTOR Activator 5), and among its related pathways/superpathways are Human cytomegalovirus infection and Toll-like Receptor Signaling Pathway. The drugs Guaifenesin and Methadone have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and testes, and related phenotype is neoplasm.

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis B virus, which is transmitted by sexual contact, transmitted by blood transfusions, and transmitted by fomites like needles or syringes. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 76 Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) that affects the liver. It... more...

Related Diseases for Hepatitis B

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis B via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 632)
# Related Disease Score Top Affiliating Genes
1 hepatitis d 33.3 F2 GPT IFNA2
2 hepatitis 32.5 AFP F2 GPT IFNA1 IFNA2 IFNAR2
3 liver disease 32.1 AFP ALB F2 GPT IFNA1 TNF
4 viral infectious disease 32.0 GPT IFNA1 IFNA2 IFNG TNF
5 hepatitis c 31.4 GPT IFNA1 IFNA2 IFNAR2 IFNG TNF
6 infantile liver failure syndrome 1 31.1 ALB F2 GPT
7 liver cirrhosis 31.0 AFP ALB F2 GPT IFNA1
8 viral hepatitis 30.9 AFP ALB F2 GPT IFNA1 IFNA2
9 acute liver failure 30.9 ALB F2 GPT
10 human immunodeficiency virus infectious disease 30.5 APOBEC3G IFNA1 IFNG TNF
11 mumps 30.5 IFNAR2 IFNG TNF
12 cryoglobulinemia, familial mixed 30.4 IFNA1 IFNA2
13 rheumatic disease 30.4 IFNA1 IFNG TNF
14 hepatitis a 30.4 AFP ALB F2 GPT IFNG TNF
15 hepatitis e 30.4 ALB F2 GPT IFNG TNF
16 schistosomiasis 30.4 ALB F2 IFNG TNF
17 measles 30.4 IFNA1 IFNAR2 IFNG
18 demyelinating disease 30.4 IFNA1 IFNG TNF
19 nonalcoholic steatohepatitis 30.3 F2 GPT TNF
20 portal hypertension 30.3 ALB F2 GPT TNF
21 alcoholic liver cirrhosis 30.3 AFP ALB F2
22 esophageal varix 30.2 AFP ALB F2
23 hepatic encephalopathy 30.1 ALB F2 GPT TNF
24 chronic graft versus host disease 30.1 ALB IFNG TNF
25 acquired immunodeficiency syndrome 30.0 ALB IFNA1 IFNA2 IFNG TNF
26 non-a-e hepatitis 30.0 ALB F2
27 hepatic coma 30.0 ALB F2 GPT
28 peritonitis 30.0 ALB F2 TNF
29 cholecystitis 29.9 ALB F2 GPT
30 mouth disease 29.9 IFNA1 IFNG TNF
31 systemic lupus erythematosus 29.9 ALB F2 IFNA1 IFNG MBL2 TNF
32 hypersplenism 29.9 ALB F2 IFNG
33 bacterial infectious disease 29.9 IFNG MBL2 TNF
34 biliary atresia 29.9 ALB GPT SLC10A1
35 cholangitis 29.9 ALB F2 GPT TNF
36 meningitis 29.8 ALB IFNG MBL2 TNF
37 analbuminemia 29.8 ALB F2 GPT
38 autoimmune disease 29.8 IFNA1 IFNG MBL2 TNF
39 alcoholic hepatitis 29.8 ALB F2 GPT TNF
40 severe acute respiratory syndrome 29.8 IFNA1 IFNG TNF
41 typhoid fever 29.7 ALB F2 IFNG TNF
42 aspergillosis 29.7 IFNG MBL2 TNF
43 mycobacterium tuberculosis 1 29.7 IFNG MBL2 TNF
44 uveitis 29.7 IFNA2 IFNG TNF
45 fascioliasis 29.7 ALB GPT IFNG
46 leprosy 3 29.7 ALB IFNG TNF
47 visceral leishmaniasis 29.7 ALB IFNG TNF
48 opisthorchiasis 29.7 AFP GPT TNF
49 endocarditis 29.6 ALB F2 TNF
50 eclampsia 29.6 ALB F2 TNF

Graphical network of the top 20 diseases related to Hepatitis B:



Diseases related to Hepatitis B

Symptoms & Phenotypes for Hepatitis B

Symptoms:

12
  • fever
  • vomiting
  • fatigue
  • abdominal pain
  • jaundice
  • nausea
  • joint pain
  • loss of appetite
  • clay-colored bowel movements

UMLS symptoms related to Hepatitis B:


nausea and vomiting, constipation, fever, abdominal pain, pruritus, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Hepatitis B:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.1 AFP AIP ALB IFNAR2 IFNG TNF

Drugs & Therapeutics for Hepatitis B

Drugs for Hepatitis B (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 512)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 93-14-1 3516
2
Methadone Approved Phase 4,Phase 3,Not Applicable 76-99-3 4095
3
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142217-69-4 153941
4
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 143491-57-0 60877
5
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142340-99-6 60871
6
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 21645-51-2
7
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
8
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 198153-51-4 5360545
9
Tocopherol Approved, Investigational Phase 4 1406-66-2 14986
10
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99210-65-8, 215647-85-1
11
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
12
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3424-98-4 159269
13
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 302-25-0
14
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-24-8 5755
15
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Not Applicable 2921-57-5
16
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 83-43-2 6741
17
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 36791-04-5 37542
18
rituximab Approved Phase 4,Phase 2,Phase 3,Not Applicable 174722-31-7 10201696
19
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
20 tannic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
21
Ethiodized oil Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 8008-53-5
22
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
23
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
24
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
25
Lenograstim Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 135968-09-1
26
Alprostadil Approved, Investigational Phase 4,Phase 2 745-65-3 149351 5280723
27
glycyrrhizin Approved, Experimental Phase 4,Phase 3,Phase 2 1405-86-3 3495
28
Simethicone Approved Phase 4,Phase 3 8050-81-5
29
Zidovudine Approved Phase 4,Phase 2,Not Applicable 30516-87-1 35370
30
Efavirenz Approved, Investigational Phase 4,Phase 3,Not Applicable 154598-52-4 64139
31
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 155213-67-5 392622
32
leucovorin Approved Phase 4,Phase 1,Phase 2,Not Applicable 58-05-9 6006 143
33
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 2 376348-65-1 3002977
34
Sofosbuvir Approved Phase 4,Phase 3,Phase 2,Not Applicable 1190307-88-0 45375808
35
Ledipasvir Approved Phase 4,Phase 3,Phase 2 1256388-51-8 67505836
36
chloroquine Approved, Investigational, Vet_approved Phase 4,Phase 1 54-05-7 2719
37
Etanercept Approved, Investigational Phase 4 185243-69-0
38
Adalimumab Approved Phase 4 331731-18-1 16219006
39
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 62-33-9, 60-00-4 6049
40
Pentetic acid Approved Phase 4,Phase 3,Phase 2 67-43-6
41
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
42
Cobicistat Approved Phase 4,Phase 3,Phase 2 1004316-88-4
43
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
44
Ibuprofen Approved Phase 4 15687-27-1 3672
45 Estradiol valerate Approved, Investigational, Vet_approved Phase 4 979-32-8
46
Levonorgestrel Approved, Investigational Phase 4,Not Applicable 17489-40-6, 797-63-7 13109
47
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
48
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
49
Polyestradiol phosphate Approved Phase 4 28014-46-2
50
Saquinavir Approved, Investigational Phase 4 127779-20-8 60787

Interventional clinical trials:

(show top 50) (show all 1695)
# Name Status NCT ID Phase Drugs
1 A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults Unknown status NCT02203357 Phase 4
2 Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients Unknown status NCT02963714 Phase 4
3 Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients Unknown status NCT02991599 Phase 4
4 Immunogenicity of Hepatitis B Vaccination Among Drug Users Unknown status NCT02959775 Phase 4
5 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
6 Adolescents' Response to Hepatitis B Vaccine Booster Dose Unknown status NCT01341275 Phase 4
7 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
8 Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation Unknown status NCT02417207 Phase 4 Entecavir combined long-term low-dose HBIG group intramuscular;Entecavir combined HBIG group short-term high-dose intravenous
9 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
10 Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
11 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
12 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
13 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
14 Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B Unknown status NCT01925820 Phase 4 Pegasys&Entecavir
15 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
16 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
17 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
18 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
19 Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection Unknown status NCT02973646 Phase 4 Entecavir or Tenofovir;Peginterferon Alfa-2B
20 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
21 Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
22 Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues Unknown status NCT02362490 Phase 4 peginterferon alpha 2a
23 The Clinical Trial of the Anti Hepatitis B Placenta Transfer Factor Injection Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
24 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4 telbivudine plus adefovir;lamivudine plus adefovir
25 Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
26 Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy Unknown status NCT01928511 Phase 4 peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly;Nucleos(t)ide analogue therapy
27 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
28 Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults Unknown status NCT02822547 Phase 4 Peginterferon alfa-2a
29 Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B Unknown status NCT02482272 Phase 4 Lamivudine;Adefovir;Entecavir
30 Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
31 Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
32 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4 telbivudine
33 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
34 Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)
35 Prednisolone Priming Study in Patients With Chronic Hepatitis B Unknown status NCT00778596 Phase 4 Prednisolone;Placebo priming
36 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B Unknown status NCT00921180 Phase 4 Entecavir and peginterferon alfa-2a;Placebo and peginterferon
37 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B Unknown status NCT00917761 Phase 4 Entecavir and peginterferon (Pegasys) (52 weeks);Peginterferon (Pegasys) (96 weeks);Peginterferon (Pegasys) (48 weeks)
38 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
39 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
40 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
41 Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude Unknown status NCT02523547 Phase 4 Cavir;Baraclude
42 EFFORT Further Extension Study Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
43 Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders Unknown status NCT01126853 Phase 4
44 A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone Unknown status NCT00354653 Phase 4 LAMIVUDINE
45 Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy Unknown status NCT01768195 Phase 4 Entecavir prophylaxis
46 Tenofovir Versus Tenofovir + Telbivudine for Chronic Hepatitis B Unknown status NCT02774837 Phase 4 Tenofovir disoproxil;Telbivudine
47 Efficacies of Entecavir Add on HBeAg Negative Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment Unknown status NCT02365402 Phase 4 Entecavir
48 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
49 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4 Telbivudine
50 Efficacies of Entecavir Add on HBeAg Positive Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment Unknown status NCT02368288 Phase 4 entecavir

Search NIH Clinical Center for Hepatitis B

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatitis B cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatitis B:
Bone marrow-derived mesenchymal stem cells for treatment of liver failure
Embryonic/Adult Cultured Cells Related to Hepatitis B:
Bone marrow-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: hepatitis b

Genetic Tests for Hepatitis B

Anatomical Context for Hepatitis B

MalaCards organs/tissues related to Hepatitis B:

41
Liver, T Cells, Testes, Kidney, Bone, B Cells, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis B:

19
Liver

Publications for Hepatitis B

Articles related to Hepatitis B:

(show top 50) (show all 7911)
# Title Authors Year
1
Increased risk of anal squamous cell carcinoma in HIV-positive men with prior hepatitis B virus infection. ( 30325778 )
2019
2
Specific prognostic factors in hepatitis B virus-related and non-hepatitis B virus-related intrahepatic cholangiocarcinoma after macroscopic curative resection. ( 30480811 )
2019
3
Chylomicron mimicking solid lipid nanoemulsions encapsulated enteric minicapsules targeted to colon for immunization against hepatitis B. ( 30503974 )
2019
4
The effect of rupture of membranes and labour on the risk of hepatitis B vertical transmission: Prospective multicentre observational study. ( 30504033 )
2019
5
T cell dysfunction in chronic hepatitis B infection and liver cancer: evidence from transcriptome analysis. ( 30518547 )
2019
6
A hepatitis B vaccine booster shot at age 10 could be cost-saving in China: But is it too soon to tell? ( 30448390 )
2019
7
Acquisition rate of antibody to hepatitis B surface antigen among medical and dental students in Japan after three-dose hepatitis B vaccination. ( 30449632 )
2019
8
Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk. ( 30450681 )
2019
9
Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China. ( 30466898 )
2019
10
Core gene insertion in hepatitis B virus genotype G functions at both the encoded amino acid sequence and RNA structure levels to stimulate core protein expression. ( 30415131 )
2019
11
Peroxisome proliferator-activated receptor γ coactivator family members competitively regulate hepatitis b virus biosynthesis. ( 30419515 )
2019
12
TLR3 and TLR4 SNP variants in the liver disease resulting from hepatitis B virus and hepatitis C virus infection. ( 30421643 )
2019
13
Performance of Hepatitis B Core-Related Antigen Versus Hepatitis B Surface Antigen and Hepatitis B Virus DNA in Predicting HBeAg-positive and HBeAg-negative Chronic Hepatitis. ( 30215232 )
2019
14
Prevalence of Hepatitis B Virus (HBV) Among Blood Donors in Eastern Saudi Arabia: Results From a Five-Year Retrospective Study of HBV Seromarkers. ( 30215234 )
2019
15
Performance Evaluation of the Beckman Coulter DxN VERIS Hepatitis B Virus (HBV) Assay in Comparison With the Abbott RealTime HBV Assay. ( 30215235 )
2019
16
Hyperbranched rolling circle amplification (HRCA)-based fluorescence biosensor for ultrasensitive and specific detection of single-nucleotide polymorphism genotyping associated with the therapy of chronic hepatitis B virus infection. ( 30262063 )
2019
17
Serum miR-21 and miR-26a Levels Negatively Correlate with Severity of Cirrhosis in Patients with Chronic Hepatitis B. ( 30147020 )
2019
18
Hepatitis B virus and hepatitis delta virus subtypes circulating in Algeria and seroprevalence of HDV infection. ( 30168584 )
2019
19
Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients: a multicentric study. ( 30080685 )
2019
20
Aberrant DNA methylation profile of hepatitis B virus infection. ( 30118556 )
2019
21
Impact of an electronic medical record reminder on hepatitis B vaccine initiation and completion rates among insured adults with diabetes mellitus. ( 29958736 )
2019
22
Solid-state [<sup>13</sup>C-<sup>15</sup>N] NMR resonance assignment of hepatitis B virus core protein. ( 29450824 )
2018
23
Prevalence of Hepatitis B virus and Hepatitis D virus coinfection in Western Burkina Faso and molecular characterization of the detected virus strains. ( 29432880 )
2018
24
Immunoreaction-Mediated Aggregation of Gold Nanoparticles for Sensitive and Selective Assay of Hepatitis B Surface Antigen. ( 29448537 )
2018
25
Identification of novel susceptibility loci associated with hepatitis B surface antigen seroclearance in chronic hepatitis B. ( 29975729 )
2018
26
Distribution characteristics of cells in splenomegaly due to hepatitis B-related cirrhotic portal hypertension and their clinical importance. ( 29781346 )
2018
27
A Case of Acute Autoimmune Hepatitis Superimposed on Chronic Hepatitis B Infection. ( 29805819 )
2018
28
A cross-sectional study of the relationship between infant Thimerosal-containing hepatitis B vaccine exposure and attention-deficit/hyperactivity disorder. ( 29413097 )
2018
29
Adalimumab therapy in hepatitis B virus-negative polyarteritis nodosa: A case report. ( 29923995 )
2018
30
PREVALENCE OF OCCULT HEPATITIS B IN A POPULATION FROM THE BRAZILIAN AMAZON REGION. ( 29446468 )
2018
31
Hepatitis B virus infection and the risk of cancer in the elderly US population. ( 29974477 )
2018
32
Fluorescent protein tagged hepatitis B virus capsid protein with long glycine-serine linker that supports nucleocapsid formation. ( 29447911 )
2018
33
Non-Invasive Diagnostic Criteria for Hepatocellular Carcinoma in Hepatitis B Virus-Endemic Areas: Is Cirrhosis Indispensable? ( 29353268 )
2018
34
Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections. ( 29775812 )
2018
35
Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B. ( 29447614 )
2018
36
Facile synthesis of MoS<sub>2</sub>@Cu<sub>2</sub>O-Pt nanohybrid as enzyme-mimetic label for the detection of the Hepatitis B surface antigen. ( 28982091 )
2018
37
Effect of tenofovir on renal function in patients with chronic hepatitis B. ( 29443737 )
2018
38
Silencing Retinoid X Receptor Alpha Expression Enhances Early-Stage Hepatitis B Virus Infection In Cell Cultures. ( 29437960 )
2018
39
Hepatitis B vaccination coverage among health-care workers in Africa: A systematic review and meta-analysis. ( 29970299 )
2018
40
Molecular evolution and phylodynamics of hepatitis B virus infection circulating in Iran. ( 29442226 )
2018
41
Different interventional criteria for chronic hepatitis B pregnant women with HBeAg(+) or HBeAg(-): Epidemiological data from Shaanxi, China. ( 29979437 )
2018
42
Impact of viral hepatitis B status on outcomes of intrahepatic cholangiocarcinoma: a meta-analysis. ( 29947010 )
2018
43
What Are the Main Differences in the Treatment of Chronic Hepatitis B between Korean Children and Adults? ( 29441758 )
2018
44
Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. ( 29388206 )
2018
45
Proteomics Based Identification of Autotaxin As An Anti-Hepatitis B Virus Factor and a Promoter of Hepatoma Cell Invasion and Migration. ( 29414802 )
2018
46
Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin. ( 29874985 )
2018
47
Amyotrophic neuralgia of atypical presentation associated with exposure to a hepatitis B vaccine. ( 29789233 )
2018
48
Hepatitis B and hepatitis D virus infections in the Central African Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing spread in asymptomatic young adults. ( 29698488 )
2018
49
Cerebral Malaria in a Patient with HIV, Hepatitis B, and Hepatitis C. ( 29974024 )
2018
50
Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characters: a pilot open-lable randomized study. ( 29452204 )
2018

Variations for Hepatitis B

Expression for Hepatitis B

Search GEO for disease gene expression data for Hepatitis B.

Pathways for Hepatitis B

Pathways related to Hepatitis B according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.89 APOBEC3G IFNA1 IFNA2 IFNAR2 LAMTOR5 TNF
2
Show member pathways
12.79 IFNA1 IFNA2 IFNAR2 IFNG MBL2 TNF
3
Show member pathways
12.64 IFNA1 IFNA2 IFNAR2 IFNG TNF
4
Show member pathways
12.23 IFNA1 IFNA2 IFNAR2 IFNG
5
Show member pathways
12.17 ALB F2 IFNG TNF
6
Show member pathways
12.12 IFNA1 IFNA2 IFNAR2 IFNG
7 12.1 IFNA1 IFNA2 IFNAR2 TNF
8
Show member pathways
12.03 IFNA1 IFNA2 IFNAR2 IFNG TNF
9 11.99 IFNA1 IFNA2 IFNG TNF
10
Show member pathways
11.93 IFNA1 IFNA2 IFNAR2 IFNG TNF
11 11.68 IFNA1 IFNA2 IFNAR2 TNF
12 11.59 IFNA2 IFNG TNF
13
Show member pathways
11.44 IFNAR2 IFNG TNF
14 11.26 AIP IFNG TNF
15
Show member pathways
11.26 IFNA1 IFNA2 IFNAR2 IFNG TNF
16 11.2 IFNA1 IFNA2 IFNAR2 IFNG
17 11.19 AFP ALB F2

GO Terms for Hepatitis B

Cellular components related to Hepatitis B according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 AFP ALB F2 IFNA1 IFNA2 IFNAR2
2 extracellular space GO:0005615 9.44 AFP ALB CPD F2 GPT IFNA1

Biological processes related to Hepatitis B according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.95 F2 IFNA1 IFNA2 IFNG TNF
2 cytokine-mediated signaling pathway GO:0019221 9.89 IFNA1 IFNA2 IFNAR2 TNF
3 cell surface receptor signaling pathway GO:0007166 9.88 F2 IFNA2 IFNAR2 IFNG
4 positive regulation of protein phosphorylation GO:0001934 9.81 F2 IFNG MIR21 TNF
5 negative regulation of gene expression GO:0010629 9.77 IFNA2 IFNG MIR17 MIR21 TNF
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.74 F2 MIR21 TNF
7 type I interferon signaling pathway GO:0060337 9.71 IFNA1 IFNA2 IFNAR2
8 response to virus GO:0009615 9.71 IFNAR2 IFNG LAMTOR5 TNF
9 positive regulation of phagocytosis GO:0050766 9.63 MBL2 MIR17 TNF
10 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.61 MIR17 MIR21
11 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.6 IFNG TNF
12 negative regulation of growth of symbiont in host GO:0044130 9.58 MBL2 TNF
13 positive regulation of metalloendopeptidase activity GO:1904685 9.56 MIR17 MIR21
14 defense response to virus GO:0051607 9.55 APOBEC3G IFNA1 IFNA2 IFNAR2 IFNG
15 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.52 MIR17 MIR21
16 negative regulation of viral process GO:0048525 9.49 APOBEC3G MBL2
17 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.48 MIR21 TNF
18 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.43 IFNG TNF
19 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.43 IFNA1 IFNA2 IFNG
20 positive regulation of vitamin D biosynthetic process GO:0060557 9.32 IFNG TNF
21 humoral immune response GO:0006959 9.26 IFNA1 IFNA2 IFNG TNF
22 positive regulation of vascular smooth muscle cell proliferation GO:1904707 8.92 MIR17 MIR21 MIR301A TNF

Molecular functions related to Hepatitis B according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 type I interferon receptor binding GO:0005132 8.96 IFNA1 IFNA2
2 cytokine activity GO:0005125 8.92 IFNA1 IFNA2 IFNG TNF

Sources for Hepatitis B